20/20 GeneSystems Inc.
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine learning and data analytics, new tests are being released which substantially improve the accuracy of biomarker blood tests for the early detection of cancers. This unique approach, being pioneered by 20/20, results in affordable, highly accurate cancer blood tests.
The Future of Cancer Detection is Here
OneTest is the first test of its kind to combine the results of multiple cancer biomarker blood tests (from a single blood draw) and personal health data using an artificial intelligence algorithm to calculate a probability score for multiple types of cancer.
Using 20/20 Hindsight:
Our innovative business model uses advanced analytics on large volumes of real world, clinically relevant patient health data collected from hospital centers where tumor biomarker testing has been used for many years.
Making Things Happen
We believe much of the innovation in cancer diagnostics for the coming decade will come from applying powerful data analytics to proven cancer biomarkers.
20/20 is using the power of realworld data and powerful A.I. driven algorithms to drive development of new tests for early detection of cancers that are affordable and accessible to hospitals all over the world.